BRITNEY FONTENOT: Open Payments
NPI 1790968832 · VILLE PLATTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 46 payments from 16 companies in 2025. Trend: 2023 $1,104 · 2024 $1,133 · 2025 $862
Food & beverage: $862
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $152 |
| GlaxoSmithKline, LLC. | 6 | $118 |
| Lilly USA, LLC | 5 | $91 |
| Axsome Therapeutics, Inc. | 3 | $82 |
| AstraZeneca Pharmaceuticals LP | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| ABBVIE INC. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 3 | $49 |
| PFIZER INC. | 1 | $22 |
Products named: GEMTESA, TRELEGY ELLIPTA, MOUNJARO, Auvelity, REXULTI, CAPLYTA, VRAYLAR, FANAPT.
Industry payments across LA — which companies pay providers there.
